GGrantIndex
← Leaderboards

Sarah H Heil

University Of Vermont &St Agric College

Google Scholar ↗PubMed ↗ORCID ↗
$14,001,642
Attributed
$16,407,951
Total exposure
15
Grants
11
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.1M · FY2005–25
$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$16,407,951 · 15

By mechanism

R01$10,757,496 · 5
U54$1,809,032 · 1
P20$1,374,686 · 1
R34$1,130,400 · 2
T32$779,039 · 1
M01$405,798 · 4

Top collaborators

Most similar at University Of Vermont &St Agric College

Same institution · by research overlap

Others in their field

Top investigators on “Pregnancy”

Research focus

PregnancyWomanParticipantProtocols DocumentationOpioidWithdrawalPharmaceutical PreparationsPregnant WomenIncentivesVermontBaseUniversitiesInnovationPregnantReportingBirthClinicSiteMothersRandomizedNeonateNeonatalBehavioralSafety

Grant awards (45)

Behavioral Pharmacology of Human Drug Use Disorders$416,044
T32 · FY2025 · DA
Behavioral Pharmacology of Human Drug Use Disorders$208,557
T32 · FY2024 · DA
Behavioral Pharmacology of Human Drug Use Disorders$154,438
T32 · FY2023 · DA
Medically-supervised withdrawal vs. agonist maintenance in the treatment of pregnant women with opioid use disorder: Maternal, fetal, and neonatal outcomes$649,921
R01 · FY2022 · DA
Low Nicotine Content Cigarettes in Vulnerable Populations: Pregnant Women$353,445
U54 · FY2022 · DA · contact PI
Medically-supervised withdrawal vs. agonist maintenance in the treatment of pregnant women with opioid use disorder: Maternal, fetal, and neonatal outcomes$652,553
R01 · FY2021 · DA
Low Nicotine Content Cigarettes in Vulnerable Populations: Pregnant Women$354,683
U54 · FY2021 · DA · contact PI
Medically-supervised withdrawal vs. agonist maintenance in the treatment of pregnant women with opioid use disorder: Maternal, fetal, and neonatal outcomes$658,011
R01 · FY2020 · DA
Low Nicotine Content Cigarettes in Vulnerable Populations: Pregnant Women$356,029
U54 · FY2020 · DA · contact PI
Medically-supervised withdrawal vs. agonist maintenance in the treatment of pregnant women with opioid use disorder: Maternal, fetal, and neonatal outcomes$661,272
R01 · FY2019 · DA
Improving Effective Contraceptive use Among Opioid-Maintained Women: Stage II$593,760
R01 · FY2019 · DA · contact PI
Low Nicotine Content Cigarettes in Vulnerable Populations: Pregnant Women$361,740
U54 · FY2019 · DA · contact PI
3 of 4, Investigation of opioid exposure and neurodevelopment (iOPEN)$263,250
R34 · FY2019 · DA
3 of 4, Investigation of opioid exposure and neurodevelopment (iOPEN)$263,250
R34 · FY2019 · DA
Medically-supervised withdrawal vs. agonist maintenance in the treatment of pregnant women with opioid use disorder: Maternal, fetal, and neonatal outcomes$709,822
R01 · FY2018 · DA
Improving Effective Contraceptive use Among Opioid-Maintained Women: Stage II$593,644
R01 · FY2018 · DA · contact PI
Low Nicotine Content Cigarettes in Vulnerable Populations: Pregnant Women$383,135
U54 · FY2018 · DA · contact PI
Collaboration, Dissemination, and Education$224,198
P20 · FY2017 · GM · contact PI
Improving Effective Contraceptive use Among Opioid-Maintained Women: Stage II$587,595
R01 · FY2016 · DA · contact PI
Collaboration, Dissemination, and Education$280,947
P20 · FY2016 · GM · contact PI
Improving Effective Contraceptive use Among Opioid-Maintained Women: Stage II$584,521
R01 · FY2015 · DA · contact PI
Collaboration, Dissemination, and Education$281,070
P20 · FY2015 · GM · contact PI
Improving Effective Contraceptive use Among Opioid-Maintained Women: Stage II$604,354
R01 · FY2014 · DA · contact PI
Testing the Reliability and Validity of Pupil Diameter in Opioid-exposed neonates$418,083
R01 · FY2014 · DA · contact PI
Collaboration, Dissemination, and Education$281,065
P20 · FY2014 · GM · contact PI
Testing the Reliability and Validity of Pupil Diameter in Opioid-exposed neonates$401,360
R01 · FY2013 · DA · contact PI
Collaboration, Dissemination, and Education$307,406
P20 · FY2013 · GM · contact PI
Testing the Reliability and Validity of Pupil Diameter in Opioid-exposed neonates$418,085
R01 · FY2012 · DA · contact PI
Improving effective contraceptive use among opioid-maintained women$301,950
R34 · FY2012 · DA · contact PI
Improving effective contraceptive use among opioid-maintained women$301,950
R34 · FY2011 · DA · contact PI
Characterizing Nicotine Withdrawal in Pregnant Smokers$335,239
R01 · FY2010 · DA · contact PI
Characterizing Nicotine Withdrawal in Pregnant Smokers$338,625
R01 · FY2009 · DA · contact PI
CLINICAL TRIAL: MOTHER$118,432
M01 · FY2009 · RR · contact PI
Maternal Opioid Treatment: Human Experimental Research$460,802
R01 · FY2008 · DA · contact PI
Characterizing Nicotine Withdrawal in Pregnant Smokers$338,813
R01 · FY2008 · DA · contact PI
CLINICAL TRIAL: MOTHER$116,898
M01 · FY2008 · RR · contact PI
Maternal Opioid Treatment: Human Experimental Research$21,178
R01 · FY2008 · DA · contact PI
Maternal Opioid Treatment: Human Experimental Research$433,996
R01 · FY2007 · DA · contact PI
MOTHER$146,529
M01 · FY2007 · RR · contact PI
Maternal Opioid Treatment: Human Experimental Research$434,527
R01 · FY2006 · DA · contact PI
MOTHER$23,939
M01 · FY2006 · RR · contact PI
Maternal Opioid Treatment: Human Experimental Research$432,054
R01 · FY2005 · DA
Early Abstinence's Effect on Later Abstinence in Smokers$75,750
R03 · FY2005 · DA
Maternal Opioid Treatment: Human Experimental Research$429,281
R01 · FY2004 · DA
Early Abstinence's Effect on Later Abstinence in Smokers$75,750
R03 · FY2004 · DA